Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Income from Non-Controlling Interests (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Income from Non-Controlling Interests for 7 consecutive years, with -$1.8 million as the latest value for Q4 2025.

  • Quarterly Income from Non-Controlling Interests rose 24.24% to -$1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.0 million through Dec 2025, down 5.56% year-over-year, with the annual reading at -$8.0 million for FY2025, 5.56% down from the prior year.
  • Income from Non-Controlling Interests hit -$1.8 million in Q4 2025 for BridgeBio Pharma, up from -$2.2 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $7.3 million in Q2 2022 to a low of -$8.0 million in Q1 2021.
  • Historically, Income from Non-Controlling Interests has averaged -$2.7 million across 5 years, with a median of -$2.4 million in 2023.
  • Biggest five-year swings in Income from Non-Controlling Interests: surged 227.44% in 2022 and later tumbled 138.43% in 2023.
  • Year by year, Income from Non-Controlling Interests stood at -$5.1 million in 2021, then surged by 41.65% to -$3.0 million in 2022, then rose by 26.82% to -$2.2 million in 2023, then dropped by 7.29% to -$2.3 million in 2024, then rose by 24.24% to -$1.8 million in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for BBIO at -$1.8 million in Q4 2025, -$2.2 million in Q3 2025, and -$1.9 million in Q2 2025.